Ombitasvir/Paritaprevir/Ritonavir
- Generic Name
- Ombitasvir/Paritaprevir/Ritonavir
- Indication
用于治疗成人基因1型慢性丙型肝炎，包括无肝硬化或伴代偿期肝硬化的患者。该治疗方案是全口服的、无干扰素、可联合或不联合利巴韦林。
Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium
Completed
- Conditions
- Chronic Hepatitis C, Genotype 1 or 4
- Interventions
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 314
- Registration Number
- NCT02581163
Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada
Completed
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 565
- Registration Number
- NCT02581189
Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects
- First Posted Date
- 2015-08-28
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 18
- Registration Number
- NCT02534870
- Locations
- 🇨🇳
Site Reference ID/Investigator# 137655, Shanghai, China
ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis
Phase 3
Completed
- Conditions
- Chronic Hepatitis C Virus (HCV)
- Interventions
- First Posted Date
- 2015-08-07
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 104
- Registration Number
- NCT02517528
ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection
Phase 3
Completed
- Conditions
- Hepatitis C Virus (HCV)
- Interventions
- First Posted Date
- 2015-08-07
- Last Posted Date
- 2017-10-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 650
- Registration Number
- NCT02517515
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma
Phase 3
Terminated
- Conditions
- Chronic Hepatitis C Infection
- Interventions
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 3
- Registration Number
- NCT02504099
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
Phase 2
Completed
- Conditions
- Chronic Hepatitis C Infection
- Interventions
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 64
- Registration Number
- NCT02486406
- Locations
- 🇵🇷
San Jorge Children Hospital /ID# 136832, San Juan, Puerto Rico
🇺🇸Seattle Children's Hospital /ID# 137019, Seattle, Washington, United States
🇩🇪Helios Klinikum Wuppertal /ID# 142883, Wuppertal, Germany
Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease
Phase 3
Completed
- Conditions
- Hepatitis C Virus (HCV)
- Interventions
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2017-12-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 18
- Registration Number
- NCT02487199
Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults
Phase 3
Completed
- Conditions
- Hepatitis C Genotype 1aChronic Hepatitis CHepatitis C (HCV)
- Interventions
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2017-10-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 25
- Registration Number
- NCT02476617
A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil
Phase 3
Completed
- Conditions
- Chronic Hepatitis C Infection
- Interventions
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 222
- Registration Number
- NCT02442271
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath